PROSTATE CANCER ADVISOR

Prostate Cancer

Features

Metastatic Prostate Cancer: Investigators Ponder New Path to Improve Survival

Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Now Is the Time: Reconsider PSA Screening Guidelines

Over the past decade, there has been a profound increase in diagnoses of metastatic prostate cancer.
Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective

Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
Prostate Cancer CTC PSMA Status Could Guide Therapy

PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
Survival Improving in Metastatic Castration-Sensitive Prostate Cancer Population

Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.

Latest Prostate Cancer News

Radiologist preparing patient for PET-CT scanner.

PSMA PET/CT May Discriminate Clinically Significant Prostate Cancer for Biopsy

By

Natasha Persaud

January 20, 2023

Use of 68 Ga-PSMA PET/CT may avoid unnecessary biopsies in some men with equivocal PI-RADS 3 lesions on mpMRI.

Multiparametric MRI images (coronal view) demonstrating PIRADS 5 signal abnormality in the right peripheral zone of the prostate. A PIRADS 4 lesion can also be seen in the right transitional zone.

MRI-Guided Radiation Therapy Bests CT Guidance for Prostate Cancer

January 20, 2023

Benefits seen for genitourinary and gastrointestinal toxic effects

Black Men with Low-Risk Prostate Cancer Produce Less PSA

Higher Prostate Cancer Mortality Among Black Men Tied to Social Determinants of Health

By

Natasha Persaud

January 19, 2023

Prostate cancer has one of the largest racial disparities in outcomes between Black and White patients, according to investigators.

Per-Patient Costs of Metastatic Prostate Cancer Exceed $30,000

January 18, 2023

Increase in annual attributable costs observed over time, from $28,311 in 2007-2013 to $37,055 in 2014-2017

Prostate Cancer ADT Increases Bone Fracture Risk

By

Jody A. Charnow

January 13, 2023

Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.

Genitourinary Cancer Incidence and Mortality Varies by Region, Race, and Sex

By

Andrea S. Blevins Primeau, PhD, MBA

January 13, 2023

Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.

Male patient talking to doctor.

Prostate Cancer Survival Slightly Lower With Active Surveillance

By

Natasha Persaud

January 11, 2023

Data suggest that 125 men active surveillance would need to receive initial treatment to prevent 1 prostate cancer death at 10 years.

Business meeting table doctor businessmen physician practicAssociate Agreement Slipups Cost Providers Millions

Prostate Cancer Consensus Conference Offers Guide to Clinical Dilemmas

By

John Schieszer, MA

January 10, 2023

An international panel weighed in on management controversies in intermediate- and high-risk and locally advanced prostate cancer.

AI Platform Promises Improved Prostate Cancer Management

By

John Schieszer

December 29, 2022

A new product called iQuest has the potential to define the extent of cancer more accurately.

If a medical group has a predictable schedule that works for doctors, reasons should be defined.

On-Site Genetic Testing for Prostate Cancer Increases Patient Compliance

January 19, 2023

Implementation of on-site guideline-based genetic testing for prostate cancer patients increased compliance from 33.3 to 98.7%

Next post in Prostate Cancer

Multiparametric MRI images (coronal view) demonstrating PIRADS 5 signal abnormality in the right peripheral zone of the prostate. A PIRADS 4 lesion can also be seen in the right transitional zone.

MRI-Guided Radiation Therapy Bests CT Guidance for Prostate Cancer